NICE Recommends Chugai Pharmaceutical's Nemluvio for Moderate-to-Severe Atopic Dermatitis in Ages 12 and Above

MT Newswires Live

07/02

National Institute for Health and Care Excellence (NICE) has recommended Chugai Pharmaceutical's (TOKYO: 4519) Nemluvio (nemolizumab) for treating moderate-to-severe atopic dermatitis in patients aged 12 and over.

In NICE guidance published on July 2, the regulator cited the treatment's potential to address clinical needs and optimize NHS resources.

The decision follows two-year interim data from Galderma's ARCADIA extension study, presented at the Revolutionizing Atopic Dermatitis Conference, demonstrating the drug's long-term efficacy as an anti-IL-31 receptor A monoclonal antibody.

Chugai developed Nemluvio, while Galderma handles global clinical development and commercialization outside Japan, according to a statement on Chugai's website.

NICE is a UK-based non-departmental public body of the Department of Health and Social Care.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2548600898"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2548600898\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2548600898?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-02 17:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2548600898","market":"us","top_or_hot":-1,"title":"NICE Recommends Chugai Pharmaceutical's Nemluvio for Moderate-to-Severe Atopic Dermatitis in Ages 12 and Above","media":"MT Newswires Live","content":"<html><body><p> National Institute for Health and Care Excellence (NICE) has recommended Chugai Pharmaceutical's (TOKYO: 4519) Nemluvio (nemolizumab) for treating moderate-to-severe atopic dermatitis in patients aged 12 and over.</p><p>In NICE guidance published on July 2, the regulator cited the treatment's potential to address clinical needs and optimize NHS resources.</p><p>The decision follows two-year interim data from Galderma's ARCADIA extension study, presented at the Revolutionizing Atopic Dermatitis Conference, demonstrating the drug's long-term efficacy as an anti-IL-31 receptor A monoclonal antibody.</p><p>Chugai developed Nemluvio, while Galderma handles global clinical development and commercialization outside Japan, according to a statement on Chugai's website.</p><p>NICE is a UK-based non-departmental public body of the Department of Health and Social Care.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NICE Recommends Chugai Pharmaceutical's Nemluvio for Moderate-to-Severe Atopic Dermatitis in Ages 12 and Above</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNICE Recommends Chugai Pharmaceutical's Nemluvio for Moderate-to-Severe Atopic Dermatitis in Ages 12 and Above\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-07-02 17:48</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> National Institute for Health and Care Excellence (NICE) has recommended Chugai Pharmaceutical's (TOKYO: 4519) Nemluvio (nemolizumab) for treating moderate-to-severe atopic dermatitis in patients aged 12 and over.</p><p>In NICE guidance published on July 2, the regulator cited the treatment's potential to address clinical needs and optimize NHS resources.</p><p>The decision follows two-year interim data from Galderma's ARCADIA extension study, presented at the Revolutionizing Atopic Dermatitis Conference, demonstrating the drug's long-term efficacy as an anti-IL-31 receptor A monoclonal antibody.</p><p>Chugai developed Nemluvio, while Galderma handles global clinical development and commercialization outside Japan, according to a statement on Chugai's website.</p><p>NICE is a UK-based non-departmental public body of the Department of Health and Social Care.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BFMHRM44.USD","symbol_name":"NEUBERGER BERMAN GLOBAL EQUITY MEGATRENDS \"A\" (USD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2548600898","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2548600898","pubTimestamp":1751449713,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"National Institute for Health and Care Excellence  has recommended Chugai Pharmaceutical's  Nemluvio  for treating moderate-to-severe atopic dermatitis in patients aged 12 and over.In NICE guidance published on July 2, the regulator cited the treatment's potential to address clinical needs and optimize NHS resources.The decision follows two-year interim data from Galderma's ARCADIA extension study, presented at the Revolutionizing Atopic Dermatitis Conference, demonstrating the drug's long-term efficacy as an anti-IL-31 receptor A monoclonal antibody.Chugai developed Nemluvio, while Galderma handles global clinical development and commercialization outside Japan, according to a statement on Chugai's website.NICE is a UK-based non-departmental public body of the Department of Health and Social Care.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BFMHRM44.USD":"NEUBERGER BERMAN GLOBAL EQUITY MEGATRENDS \"A\" (USD) ACC","BK4023":"应用软件","NICE":"NICE系统","BK4543":"AI","BK4566":"资本集团"},"translate_title":"NICE推荐中外制药的Nemluvio治疗12岁及以上中重度特应性皮炎","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NICE":1},"content_text":"National Institute for Health and Care Excellence (NICE) has recommended Chugai Pharmaceutical's (TOKYO: 4519) Nemluvio (nemolizumab) for treating moderate-to-severe atopic dermatitis in patients aged 12 and over.In NICE guidance published on July 2, the regulator cited the treatment's potential to address clinical needs and optimize NHS resources.The decision follows two-year interim data from Galderma's ARCADIA extension study, presented at the Revolutionizing Atopic Dermatitis Conference, demonstrating the drug's long-term efficacy as an anti-IL-31 receptor A monoclonal antibody.Chugai developed Nemluvio, while Galderma handles global clinical development and commercialization outside Japan, according to a statement on Chugai's website.NICE is a UK-based non-departmental public body of the Department of Health and Social Care.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}